Unknown

Dataset Information

0

Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays.

ABSTRACT: Increasing evidence suggests that some newly emerged SARS-CoV-2 variants of concern (VoCs) resist neutralization by antibodies elicited by the early-pandemic wild-type virus. We applied neutralization tests to paired recoveree sera (n = 38) using clinical isolates representing the first wave (D614G), VoC1, and VoC2 lineages (B.1.1.7 and B 1.351). Neutralizing antibodies inhibited contemporary and VoC1 lineages, whereas inhibition of VoC2 was reduced 8-fold, with 50% of sera failing to show neutralization. These results provide evidence for the increased potential of VoC2 to reinfect previously SARS-CoV-infected individuals. The kinetics of NAbs in different patients showed similar decline against all variants, with generally low initial anti-B.1.351 responses becoming undetectable, but with anti-B.1.1.7 NAbs remaining detectable (>20) for months after acute infection.

SUBMITTER: Virtanen J 

PROVIDER: S-EPMC8229637 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays.

Virtanen Jenni J   Uusitalo Ruut R   Korhonen Essi M EM   Aaltonen Kirsi K   Smura Teemu T   Kuivanen Suvi S   Pakkanen Sari H SH   Mero Sointu S   Patjas Anu A   Riekkinen Marianna M   Kantele Anu A   Nurmi Visa V   Hedman Klaus K   Hepojoki Jussi J   Sironen Tarja T   Huhtamo Eili E   Vapalahti Olli O  

Viruses 20210526 6

Increasing evidence suggests that some newly emerged SARS-CoV-2 variants of concern (VoCs) resist neutralization by antibodies elicited by the early-pandemic wild-type virus. We applied neutralization tests to paired recoveree sera (<i>n</i> = 38) using clinical isolates representing the first wave (D614G), VoC1, and VoC2 lineages (B.1.1.7 and B 1.351). Neutralizing antibodies inhibited contemporary and VoC1 lineages, whereas inhibition of VoC2 was reduced 8-fold, with 50% of sera failing to sho  ...[more]

Similar Datasets

Unknown Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
| S-EPMC8188728 | biostudies-literature
Unknown Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
| S-EPMC8216260 | biostudies-literature
Unknown Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
| S-EPMC8402859 | biostudies-literature
Unknown SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies.
| S-EPMC7941631 | biostudies-literature
Unknown Evaluation of MERS-CoV Neutralizing Antibodies in Sera Using Live Virus Microneutralization Assay.
| S-EPMC7121888 | biostudies-literature
Unknown SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
| S-EPMC7980144 | biostudies-literature
Unknown Competitive detection of influenza neutralizing antibodies using a novel bivalent fluorescence-based microneutralization assay (BiFMA).
| S-EPMC4480155 | biostudies-literature
Unknown Replication Kinetics of B.1.351 and B.1.1.7 SARS-CoV-2 Variants of Concern Including Assessment of a B.1.1.7 Mutant Carrying a Defective ORF7a Gene.
| S-EPMC8227137 | biostudies-literature
Unknown A high throughput reporter virus particle microneutralization assay for quantitation of Zika virus neutralizing antibodies in multiple species.
| S-EPMC8064526 | biostudies-literature
Unknown Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization Assays.
| S-EPMC7448638 | biostudies-literature